Nuvation Bio Inc Market Cap ($1.64 Billion)
Market Cap & Net Worth: Nuvation Bio Inc (NUVB)
Nuvation Bio Inc market cap. Nuvation Bio Inc (NYSE:NUVB) has a market capitalization of $1.64 Billion ($1.64 Billion) as of November 4, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #6613 globally and #2102 in its home market, demonstrating a 3.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvation Bio Inc's stock price $4.69 by its total outstanding shares 350123233 (350.12 Million). Also see Nuvation Bio Inc (NUVB) cash flow conversion for how efficiently the company converts equity into cash flow.
Nuvation Bio Inc Market Cap History (2020–2026)
Nuvation Bio Inc market cap history from 2020 to 2026. Data shows change from $4.10 Billion to $1.64 Billion (-11.50% CAGR). Check Nuvation Bio Inc (NUVB) share price today for real-time trading data and today's change.
Nuvation Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvation Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NUVB year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
49.87x
Nuvation Bio Inc's market cap is 49.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $931.33 Million | $7.87 Million | -$567.94 Million | 118.29x | N/A |
| 2025 | $3.14 Billion | $62.90 Million | -$204.63 Million | 49.87x | N/A |
Competitor Companies of NUVB by Market Capitalization
Companies near Nuvation Bio Inc in the global market cap rankings as of November 4, 2026. Also see total assets of Nuvation Bio Inc for a full breakdown of the balance sheet.
Key companies related to Nuvation Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Nuvation Bio Inc (2020–2026)
Market capitalization of Nuvation Bio Inc from 2020 to today. Between 2020 and today, Nuvation Bio Inc's market cap moved from $4.10 Billion to $ 1.64 Billion, with a yearly change of -11.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.64 Billion | -47.66% |
| 2025 | $3.14 Billion | +236.84% |
| 2024 | $931.33 Million | +76.16% |
| 2023 | $528.69 Million | -21.35% |
| 2022 | $672.24 Million | -77.41% |
| 2021 | $2.98 Billion | -27.35% |
| 2020 | $4.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Nuvation Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.64 Billion USD |
| MoneyControl | $1.64 Billion USD |
| MarketWatch | $1.64 Billion USD |
| marketcap.company | $1.64 Billion USD |
| Reuters | $1.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more